Results 111 to 120 of about 1,015,995 (302)

Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency

Advanced Materials, EarlyView.
As lipid nanoparticle (LNP) systems are the leading platform for in vivo nucleic acid delivery, improving transfection potency of these systems is of considerable interest. In this work, we explored a post‐mixing formulation method involving a two‐step buffer exchange that increased the number of mRNA copies within each LNP while reducing the number of
Yao Zhang, Jerry Leung, Judy Cheng, Arash Momeni, Albert Kamanzi, Ariadne Tuckmantel Bido, Suiyang Liao, Emma Kang, Colton Strong, Christian J. Kastrup, Sabrina Leslie, Miffy Hok Yan Cheng, Pieter R. Cullis   +12 more
wiley   +1 more source

The global burden and epidemiology of invasive non-typhoidal Salmonella infections

Human Vaccines & Immunotherapeutics, 2019
Invasive non-typhoidal Salmonella (iNTS) disease has emerged as a major public health concern. Yet, understanding of the global burden is incomplete, limited particularly by the breadth of blood culture-based surveillance systems that are able to ...
Ruchita Balasubramanian, Justin Im, Jung-Seok Lee, Hyon Jin Jeon, Ondari D. Mogeni, Jerome H. Kim, Raphaël Rakotozandrindrainy, Stephen Baker, Florian Marks   +8 more
doaj   +1 more source

Charge‐Reversed Lipid Nanoparticles Enable Encapsulation of Pt2L4 Nanocages for In vivo Anti‐Cancer Treatment

Advanced Materials, EarlyView.
Charge‐reversed lipid nanoparticles (revLNPs) enable efficient encapsulation and delivery of cationic Pt2L4 nanocages. Encapsulation preserves potent anticancer activity while improving circulation, reducing vascular leakage, and promoting favorable biodistribution in vivo.
Renzo A. Knol, Bochuan Hu, Eduard O. Bobylev, Martina Farber, Petrus C. M. Laan, Thomas J. F. Kock, Bauke Fontein, Johanna Erbani, Oscar Escalona‐Rayo, Seline S. Roose, Tom Keijer, Gabriel Forn‐Cuní, B. Ewa Snaar‐Jagalska, Leila Akkari, Joost N. H. Reek, Alexander Kros, Dennis Aschmann   +16 more
wiley   +1 more source

Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses

npj Vaccines
Potent cellular immune responses are crucial for the development of effective vaccines against cancer and chronic infectious diseases. Here, we formulate Nexavant (NVT), a well-characterized TLR3 agonist, into lipid nanoparticles (LNPs) using either the ...
Kwang Hyun Ko, Seung-Hwan Lee, Young-Ho Choi, Soon Myung Kang, Hyun-Suk Yang, So Min Lee, Eun Bi Jo, Hyun Shik Bae, Seung-Beom Hong, Dong-Ho Kim, Seung Bin Cha   +10 more
doaj   +1 more source

Biomass DNA: An Emerging Building Block for Advanced Materials

Advanced Materials, EarlyView.
Biomass DNA is rapidly emerging from its traditional role as a genetic blueprint to serve as a versatile abundant, highly programmable polymeric building block. This review highlights the transformation of macroscopic bulk biomass DNA into next generation of functional materials, spanning from dynamic hydrogels, sustainable bioplastics, and high ...
Yuwei Hu, Itamar Willner, Li Niu
wiley   +1 more source

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies

Infectious Diseases and Therapy, 2020
Introduction Two phase 3 studies in adolescents and young adults demonstrated that MenB-FHbp, a meningococcal serogroup B (MenB) vaccine, elicits protective immune responses after 2 or 3 doses based on serum bactericidal antibody assays using human ...
Johannes Beeslaar, Judith Absalon, Annaliesa S. Anderson, Joseph J. Eiden, Paul Balmer, Shannon L. Harris, Thomas R. Jones, Robert E. O’Neill, Jean-Louis Pregaldien, David Radley, Roger Maansson, John Ginis, Amit Srivastava, John L. Perez   +13 more
doaj   +1 more source

Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial [PDF]

, 2008
Background Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine.
Gerd Pluschke, Sarah C. Gilbert, Hill, Adrian, Hutchings, Claire, Gilbert Sarah C., Sinden, Robert, Gilbert, Sarah C., Zurbriggen Rinaldo, Vogel, Denise, Jack L. Williams, Andrews Laura, Westerfeld Nicole, Andrews, Laura, David W. Porter, Thompson, Fiona, Okitsu, Shinji, Ian Poulton, Shinji L. Okitsu, Denise Vogel, Dunachie Susanna, Thompson Fiona M., Berthoud, Tamara, Porter David W., Pluschke, Gerd, Sarah C Gilbert, Sinden Robert, Poulton Ian, Fiona M Thompson, Zurbriggen, Rinaldo, Rinaldo Zurbriggen, Susanna Dunachie, Westerfeld, Nicole, Tamara Berthoud, Todryk, Stephen, Okitsu Shinji L., Hill Adrian V. S., Correa Simon, Berthoud Tamara, David W Porter, Nicole Westerfeld, Todryk Stephen, Porter, David, Correa, Simon, Pluschke Gerd, Poulton, Ian, Hutchings Claire, Vogel Denise, Shinji L Okitsu, Fiona M. Thompson, Jack L Williams, Simon Correa, Laura Andrews, Dunachie, Susanna, Adrian V S Hill, Robert Sinden, Stephen Todryk, Williams, Jack, Claire Hutchings, Williams Jack L., Thompson, Fiona M., Williams, Jack L., Porter, David W., Okitsu, Shinji L., Hill, Adrian V. S.   +63 more
core   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Impact of Specific Pattern Mutations on Plaque Formation and Attenuation Properties of Dengue Virus Serotype 3

Advances in Virology
Dengue fever is a major public health problem in several countries, including Thailand. The development of an effective dengue vaccine against all four serotypes is important for controlling the disease.
Panumas Sun-Arlee, Surat Punyahathaikul, Ekkarat Rodpai, Kunjimas Ketsuwan, Duangnapa Wanlayaporn, Sasiporn Ruangdachsuwan, Jukrapun Komaikul, Thitigun Jaimipuk, Sanjira Juntarapornchai, Chompunuch Boonarkart, Anan Jongkaewwattana, Sutee Yoksan, Prasert Auewarakul, Promsin Masrinoul   +13 more
doaj   +1 more source

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. [PDF]

, 2008
BACKGROUND: The RTS,S/AS malaria vaccine is being developed for delivery through the World Health Organization's Expanded Program on Immunization (EPI).
Machera, Francisca, Membi, Christopher, Kubhoja, Sulende, Cohen, Joe, Abdulla, Salim, Aebi, Thomas, Oberholzer, Rolf, Omari, Said, Ballou, W Ripley, Jumanne, Ajuza, Schellenberg, David M, Dubois, Marie-Claude, Salim, Nahya, Lievens, Marc, Carter, Terrell, Shomari, Mwanjaa, Urassa, Alwisa, Juma, Omar, Leach, Amanda, Demoitié, Marie-Ange, Vekemans, Johan, Mshinda, Hassan, Villafana, Tonya, Tanner, Marcel   +23 more
core   +1 more source